Internet Download Accelerator v2.0.1.532 serial key or number

NX Series

Constant and Variable Torque Variable

Speed Drives for Induction Motors

63-2600—1

REFER TO THE START-UP QUICK GUIDE BELOW DURING INSTALLATION AND COMMISSIONING.

IF ANY PROBLEMS OCCUR, PLEASE CONTACT YOUR LOCAL DISTRIBUTOR.

Start-up Quick Guide

1. Check that the delivery corresponds to your order, see Chapter 3.

2. Before taking any commissioning actions read carefully the safety instructions in Chapter

1.

3. Before the mechanical installation, check the minimum clearances around the unit and

check the ambient conditions in Chapter 5.

4. Check the size of the motor cable, mains cable, mains fuses and check the cable

connections, read Chapters 6.1.1.1 to 6.1.1.5..

5. Follow the installation instructions, see Chapter 6.1.5.

6. Control connections are explained in Chapter 6.2.1.

7. If the Start-Up wizard is active, select the language of the keypad and the application

you want to use and confirm by pressing the Enter button. If the Start-Up wizard is not

active, follow the instructions 7a and 7b.

7a. Select the language of the keypad from the Menu M6, page 6.1. Instructions on using

the keypad are given in Chapter 7.

7b. Select the application you want to use from the Menu M6, page 6.2. Instructions on

using the keypad are given in Chapter 7.

8. All parameters have factory default values. In order to ensure proper operation, check

the rating plate data for the values below and the corresponding parameters of

parameter group G2.1.

• nominal voltage of the motor

• nominal frequency of the motor

• nominal speed of the motor

• nominal current of the motor

• motor cosϕ

All parameters are explained in the All in One Application Manual.

9. Follow the commissioning instructions, see Chapter 8.

10. NX_ Frequency Drive is now ready for use.

The Manufacturer is not responsible for the use of the frequency drives

outside the instructions provided.

CONTENTS

NX USER’S MANUAL

INDEX

1 SAFETY

2 EU DIRECTIVE

3 RECEIPT OF DELIVERY

4 TECHNICAL DATA

5 INSTALLATION

6 CABLING AND CONNECTIONS

7 CONTROL KEYPAD

8 COMMISSIONING

9 FAULT TRACING

THE NX FREQUENCY DRIVE USER'S MANUAL

AND THE APPLICATION MANUAL

The User's Manual will provide the necessary information about the installation, commissioning

and operation of NX Frequency Drives. It is recommended that these instructions are studied,

before powering up the frequency drive for the first time.

The Application Manual provides information about the different applications included in the

standard frequency drive. Should these applications not meet the requirements of the process,

contact Honeywell for information on special applications.

This manual is available in both paper and electronic editions. It is recommended that the

electronic version be used where possible as it contains several links and cross-references to

other locations in the manual which makes it easier for the reader to move around in the manual,

to check and find things faster.

NX User's Manual

Index

1. SAFETY....................................................................................................................................6

1.1 WARNINGS..............................................................................................................................................6

1.2 SAFETY INSTRUCTIONS............................................................................................................................6

1.3 GROUNDING AND GROUND FAULT PROTECTION.........................................................................................7

1.4 RUNNING THE MOTOR..............................................................................................................................7

2. DIRECTIVES.............................................................................................................................8

2.1 CE MARKING...........................................................................................................................................8

2.2 EMC DIRECTIVE......................................................................................................................................8

2.2.1 General...............................................................................................................................................8

2.2.2 Technical criteria ................................................................................................................................8

2.2.3 NX frequency drive EMC classification...............................................................................................8

2.2.4 Manufacturer's declaration of conformity............................................................................................9

2.3 UL-LABEL................................................................................................................................................9

3. RECEIPT OF SHIPMENT .......................................................................................................13

3.1 TYPE DESIGNATION CODE ......................................................................................................................13

3.2 STORAGE..............................................................................................................................................13

3.3 MAINTENANCE.......................................................................................................................................14

3.4 WARRANTY ...........................................................................................................................................14

4. TECHNICAL DATA ................................................................................................................15

4.1 INTRODUCTION......................................................................................................................................15

4.2 POWER RATINGS ...................................................................................................................................17

4.2.1 NX_5 – Mains voltage 380—500 V ..................................................................................................17

4.2.2 NX_6 – Mains voltage 525—690 V ..................................................................................................18

4.2.3 NX_2 – Mains voltage 208—240 V ..................................................................................................19

4.3 BRAKE RESISTOR RATINGS ....................................................................................................................20

4.4 TECHNICAL DATA...................................................................................................................................22

5. INSTALLATION......................................................................................................................24

5.1 MOUNTING ............................................................................................................................................24

5.2 COOLING...............................................................................................................................................34

5.2.1 FR4 to FR9 .......................................................................................................................................34

5.2.2 Standalone units (FR10 to FR12).....................................................................................................35

5.3 POWER LOSS ........................................................................................................................................36

5.3.1 Power loss as function of switching frequency .................................................................................36

6. CABLING AND CONNECTIONS............................................................................................40

6.1 POWER UNIT .........................................................................................................................................40

6.1.1 Power connections ...........................................................................................................................40

6.1.1.1 Mains and motor cables ................................................................................................................40

6.1.1.2 DC supply and brake resistor cables.............................................................................................41

6.1.1.3 Control cable .................................................................................................................................41

6.1.1.4 Cable and fuse sizes, NXS B and NXS A......................................................................................41

6.1.1.5 Cable and fuse sizes, NXS C ........................................................................................................42

6.1.1.6 Cable and fuse sizes, NX_A, FR10 to FR12 .................................................................................42

6.1.1.7 Cable and fuse sizes, NX_C, FR10 to FR12 .................................................................................43

6.1.2 Understanding the power unit topology ............................................................................................43

6.1.3 Changing EMC protection class from H to T ....................................................................................44

6.1.4 Mounting of cable accessories .........................................................................................................46

6.1.5 Installation instructions .....................................................................................................................48

6.1.5.1 Stripping lengths of motor and mains cables.................................................................................50

6.1.5.2 NX frequency drive frames and installation of cables....................................................................51

6.1.6 Cable installation and the UL standards...........................................................................................58

6.1.7 Cable and motor insulation checks...................................................................................................59

6.2 CONTROL UNIT ......................................................................................................................................60

6.2.1 NXS and NXP single phase input applications 380-500 VAC ..........................................................61

6.2.2 Control connections..........................................................................................................................62

6.2.2.1 Control cables................................................................................................................................63

6.2.2.2 Galvanic isolation barriers .............................................................................................................63

6.2.3 Control terminal signals ....................................................................................................................65

6.2.3.1 Digital input signal inversions ........................................................................................................66

6.2.3.2 Jumper selections on the OPT-A1 basic board .............................................................................67

7. CONTROL KEYPAD ..............................................................................................................69

7.1 INDICATIONS ON THE KEYPAD DISPLAY ...................................................................................................69

7.1.1 Drive status indications.....................................................................................................................69

7.1.2 Control place indications ..................................................................................................................70

7.1.3 Status LEDs (green – green – red)...................................................................................................70

7.1.4 Text lines ..........................................................................................................................................71

7.2 KEYPAD PUSH-BUTTONS........................................................................................................................72

7.2.1 Button descriptions ...........................................................................................................................72

7.3 NAVIGATION ON THE CONTROL KEYPAD ..................................................................................................73

7.3.1 Monitoring menu (M1) ......................................................................................................................75

7.3.2 Parameter menu (M2) ......................................................................................................................76

7.3.3 Keypad control menu (M3) ...............................................................................................................78

7.3.3.1 Selection of control place ..............................................................................................................78

7.3.3.2 Keypad reference ..........................................................................................................................79

7.3.3.3 Keypad direction............................................................................................................................79

7.3.3.4 Stop button activated.....................................................................................................................79

7.3.4 Active faults menu (M4)....................................................................................................................80

7.3.4.1 Fault types .....................................................................................................................................81

7.3.4.2 Fault codes....................................................................................................................................82

7.3.4.3 Fault time data record....................................................................................................................84

7.3.5 Fault history menu (M5)....................................................................................................................85

7.3.6 System menu (M6) ...........................................................................................................................86

7.3.6.1 Language selection .......................................................................................................................89

7.3.6.2 Application selection......................................................................................................................89

7.3.6.3 Parameter copy .............................................................................................................................90

7.3.6.4 Parameter comparison ..................................................................................................................92

7.3.6.5 Security..........................................................................................................................................93

7.3.6.6 Keypad settings .............................................................................................................................95

7.3.6.7 Hardware settings..........................................................................................................................96

7.3.6.8 System info....................................................................................................................................99

7.3.7 Expander board menu (M7)............................................................................................................103

7.4 FURTHER KEYPAD FUNCTIONS .............................................................................................................104

8. COMMISSIONING ................................................................................................................105

8.1 SAFETY...............................................................................................................................................105

8.2 COMMISSIONING OF THE FREQUENCY DRIVE.........................................................................................105

9. FAULT TRACING .................................................................................................................108

1

6(110) Safety

1. SAFETY

ONLY A COMPETENT ELECTRICIAN SHOULD CARRY OUT

THE ELECTRICAL INSTALLATION

1.1 Warnings

WARNING

1

The NX frequency drive is meant for fixed installations only.

2

Do not perform any measurements when the frequency drive is

connected to the mains. The motor terminals U, V, W and the DClink/brake

resistor terminals –/+ are live when the NX is connected to

mains, even if the motor is not running.

3

Do not perform any voltage withstand tests on any part of the NX.

4

The frequency drive has a large capacitive leakage current.

5

If the frequency drive is used as a part of a machine, the machine

manufacturer is responsible for providing the machine with a main switch

(EN 60204-1).

6

Only spare parts delivered by Honeywell can be used.

7

The motor starts at power-up if the start command is 'ON'. Furthermore,

the I/O functionalities (including start inputs) may change if parameters,

applications or software are changed. Disconnect, therefore, the motor if

an unexpected start can cause danger.

8

Prior to measurements on the motor or the motor cable, disconnect the

motor cable from the frequency drive.

9

Do not touch the IC-circuits on the circuit boards. Static voltage discharge

may damage the components.

1.2 Safety instructions

1

The components of the power unit of the frequency drive are live when

the NX is connected to mains potential. ontact with this voltage is

extremely dangerous and may cause death or severe injury. The

control unit is isolated from the potential.

2

The motor terminals U, V, W and the DC-link/brake resistor terminals –/+

are live when the NX is connected to mains, even if the motor is not

running.

3

After disconnecting the frequency drive from the mains, wait until the fan

stops and the indicators on the keypad extinguish. (if no keypad is

attached see the indicators on the cover). Wait 5 more minutes before

doing any work on the NX connections. Do not even open the cover

before this time has expired.

4

The control I/O-terminals are isolated from the mains potential. However,

the relay outputs and other I/O-terminals may have a dangerous control

voltage present even when the NX is disconnected from mains.

5

Before connecting the frequency drive to mains, ensure that the

frequency drive front and cable covers are closed.

Safety 7(110)

1

1.3 Grounding and ground fault protection

The NX frequency drive must always be grounded via a conductor connected to the grounding

terminal .

The ground fault protection inside the frequency drive protects only the drive itself against ground

faults in the motor or the motor cable.

If fault current protective switches (e.g. RCD or Ground Leakage devices) are to be used in

conjunction with the frequency drive, they must be tested with ground fault currents that are

possible to arise in fault situations.

1.4 Running the motor

Warning symbols

For your own safety please pay special attention to the instructions marked with the following

symbols:

= Dangerous voltage

WARNING

= General warning

HOT SURFACE

= Hot surface – Risk of burn

MOTOR RUN CHECK LIST

1

Before starting the motor, check that the motor is mounted properly

and ensure that the machine connected to the motor allows the

motor to be started.

2

Set the maximum motor speed (frequency) according to the motor

and the machine connected to it.

3

Before reversing the motor shaft rotation direction make sure that

WARNING this can be done safely.

4

Ensure that no power correction capacitors are connected to the

motor cable.

5

Ensure that the motor terminals are not connected to mains

potential.

8(110) DIRECTIVES

2. DIRECTIVES

2.1 CE marking

The CE marking on the product guarantees the free movement of the product within the EEA

(European Economic Area). It also guarantees that the product meets the various requirements

defined by the directive.

The NX frequency drives carry the CE label as a proof of compliance with the Low Voltage

Directive (LVD) and the Electro Magnetic Compatibility (EMC). The company SGS FIMKO has

acted as the Competent Body.

2.2 EMC directive

2.2.1 General

The EMC Directive provides that the electrical apparatus must not excessively disturb the

environment it is used in, and also, it shall have an adequate level of immunity toward other

disturbances from the same environment.

The compliance of the NX frequency drives with the EMC directive is verified with Technical

Construction Files (TCF) checked and approved by SGS FIMKO, which is a Competent Body. The

Technical Construction Files are used to authenticate the comformity of the NX frequency drives

with the Directive due to the large product family & variety of installations possibilities.

2.2.2 Technical criteria

The NX frequency drives are marketed throughout the world, a fact which makes the EMC

requirements of customers different. As far as the immunity is concerned, all NX frequency drives

are designed to fulfil even the strictest requirements, while as regards the emission level, the

customer may want to upgrade the NX's already high ability to filter electro-magnetic

disturbances.

2.2.3 NX frequency drive EMC classification

The NX frequency drives are divided into three classes, according to the level of electromagnetic

disturbances emitted. There is no difference in the functions or the control electronics between

these classes but their EMC properties vary as follows:

Class H:

NX_5 frequency drives (FR4 to FR9) and NX_2 frequency drives (FR4 to FR6) have been

designed to fulfil the requirements of the product standard IEC 61800-3+A11 for the 1st

environment restricted distribution and the 2nd environment.

The emission levels correspond to the requirements of IEC 61000-6-4.

Class L (NX_5, FR10 only):

Provides filtering for the 2 nd environment, restricted distribution according to IEC 61800-3+A11.

2

DIRECTIVES 9(110)

Class T:

The T-class drives have a small ground current and can be used with IT supplies only. If they are

used with other supplies no EMC requirements are complied with.

Class N:

The drives of this class do not provide EMC emission protection. This kind of drives are mounted

in enclosures.

All NX frequency drives fulfil all EMC immunity requirements (standards IEC 61000-6-1,

61000-6-2 and IEC 61800-3+A11).

Warning: This is a product of the restricted sales distribution class according to IEC 61800-

3. In a domestic environment this product may cause radio interference in which case the

user may be required to take adequate measures.

Note: For changing the EMC protection class of your NX frequency drive from class H to class T,

please refer to the instructions given in Chapter 6.3.1.

2.2.4 Manufacturer's declaration of conformity

The following pages present the photocopies of the Manufacturer's Declarations of Conformity

assuring the compliance of the NX frequency drives with the EMC-directives.

2.3 UL-label

The NX frequency drives are UL-listed according to the standards, based on the needed voltage

and power range. For more information contact you local Honeywell distributor. More information

of cable selection and installation can be found from chapter 5 and 6.

2

10(110) DIRECTIVES

We

Manufacturer's name:

EU DECLARATION OF CONFORMITY

Vacon Oyj

Manufacturer's address: P.O.Box 25

Runsorintie 7

FIN-65381 Vaasa

Finland

hereby declare that the product

Product name:

Model designation:

NXS/P Frequency converter

NXS/P 0003 5…. to 0520 5….

has been designed and manufactured in accordance with the following

standards:

Safety: EN50178 (1997), EN60204-1 (1996)

EN 60950 (3rd edition 2000, as relevant)

EMC: EN61800-3 (1996)+A11(2000), EN 61000-6-2

(1999), EN 61000-6-4 (2001)

and conforms to the relevant safety provisions of the Low Voltage Directive

(73/23/EEC) as amended by the Directive (93/68/EEC) and EMC Directive

89/336/EEC.

It is ensured through internal measures and quality control that the product

conforms at all times to the requirements of the current Directive and the

relevant standards.

In Vaasa, 5th of May, 2003

Vesa Laisi

President

The year the CE marking was affixed: 2002

2

Receipt of shipment 11(110)

3

We

Manufacturer's name:

EU DECLARATION OF CONFORMITY

Vacon Oyj

Manufacturer's address: P.O.Box 25

Runsorintie 7

FIN-65381 Vaasa

Finland

hereby declare that the product

Product name:

NXS/P Frequency converter

Model designation:

NXS/P 0004 6…. to 0416 6….

has been designed and manufactured in accordance with the following

standards:

Safety: EN50178 (1997), EN60204-1 (1996)

EN 60950 (3rd edition 2000, as relevant)

EMC: EN61800-3 (1996)+A11(2000), EN 61000-6-2

(1999), EN 61000-6-4 (2001)

and conforms to the relevant safety provisions of the Low Voltage Directive

(73/23/EEC) as amended by the Directive (93/68/EEC) and EMC Directive

89/336/EEC.

It is ensured through internal measures and quality control that the product

conforms at all times to the requirements of the current Directive and the

relevant standards.

In Vaasa, 17th of November, 2003

Vesa Laisi

President

The year the CE marking was affixed: 2003

3

12(110) Receipt of shipment

We

Manufacturer's name:

EU DECLARATION OF CONFORMITY

Vacon Oyj

Manufacturer's address: P.O.Box 25

Runsorintie 7

FIN-65381 Vaasa

Finland

hereby declare that the product

Product name:

NXS/P Frequency converter

Model designation:

NXS/P 0003 2…. to 0114 2….

has been designed and manufactured in accordance with the following

standards:

Safety: EN50178 (1997), EN60204-1 (1996)

EN 60950 (3rd edition 2000, as relevant)

EMC: EN61800-3 (1996)+A11(2000), EN 61000-6-2

(1999), EN 61000-6-4 (2001)

and conforms to the relevant safety provisions of the Low Voltage Directive

(73/23/EEC) as amended by the Directive (93/68/EEC) and EMC Directive

89/336/EEC.

It is ensured through internal measures and quality control that the product

conforms at all times to the requirements of the current Directive and the

relevant standards.

In Vaasa, 10th of November, 2003

Vesa Laisi

President

The year the CE marking was affixed: 2003

Note: Ask factory for other possible installation combinations.

Receipt of shipment 13(110)

3

3. RECEIPT OF SHIPMENT

The NX frequency drives have undergone rigorous tests and quality checks at the factory before

delivery. However, after unpacking the product, check that no signs of transport damages are to

be found on the product and that the delivery is complete (compare the type designation of the

product to the code below, Figure 3-1.

Should the drive have been damaged during the shipping, contact the carrier and or distributor.

If the delivery does not correspond to your order, contact the supplier immediately.

In the small plastic bag included in the delivery you will find a silver Drive modified sticker. The

purpose of the sticker is to notify the service personnel about the modifications made in the

frequency drive. Attach the sticker on the side of the frequency drive to avoid losing it. Should the

frequency drive be later modified (option board added, IP or EMC protection level changed), mark

the change in the sticker.

3.1 Type designation code

N X S 0 0 5 0 B 1 2

E n c l osure 00 Open chassis

10 Nema 1

12 Nema 12

V o l t a ge range B 208-240 Vac 3 p h a s e

A 380-500 Vac 3 p h a s e

C 525-690 Vac 3 p h a s e

M o t or Power (HP) 0005 1/2 HP

L o w overloadability: 0050 5 HP

1 0 % overload at 0400 40 HP e t c

1 0 4 deg F

Figure 3-1. NX type designation code

P r o duct Series

NXS

NXL

3.2 Storage

If the frequency drive is to be kept in store ensure that the ambient conditions are acceptable:

Storing temperature -40…+158°F (-40…70° C)

Relative humidity

3

14(110) Receipt of shipment

3.3 Maintenance

In normal conditions, the NX frequency drives are maintenance-free. However, it is recommended

the heatsink be cleared periodically with compressed air. The cooling fan can easily be changed if

necessary.

It may also be necessary to check the tightening torques of terminals at regular intervals.

3.4 Warranty

Only manufacturing defects are covered by the warranty. The manufacturer assumes no

responsibility for damages caused during or resulting from transport, receipt of the delivery,

installation, commissioning or use.

The manufacturer shall in no event and under no circumstances be held responsible for damages

and failures resulting from misuse, incorrect installation, unacceptable ambient temperature, dust,

corrosive substances or operation outside the rated specifications.

Neither can the manufacturer be held responsible for consequential damages.

The Manufacturer's period of warranty is 18 months from the delivery or 12 months from the

commissioning whichever expires first.

The local distributor may grant a warranty time different from the above. This warranty period shall

be specified in the distributor's sales and warranty terms. The manufacturer assumes no

responsibility for warranties offered by others. With all warranty issues, please contact the

distributor first.

Technical data 15(110)

4. TECHNICAL DATA

4.1 Introduction

Figure 4-1 presents the block diagram of the NX frequency drive. The frequency drive consists of

two units, the Power Unit and the Control Unit.

The three-phase AC-choke (1) at the mains end together with the DC-link capacitor (2) form an

LC-filter, which, again, together with the diode bridge produce the DC-voltage supply to the IGBT

Inverter Bridge (3) block. The AC-choke also functions as a filter against High Frequency

disturbances from the mains as well as against those caused by the frequency drive to the mains.

It, in addition, enhances the waveform of the input current to the frequency drive. The entire power

drawn by the frequency drive from the mains is active power.

The IGBT Inverter Bridge produces a symmetrical, 3-phase PWM-modulated AC-voltage to the

motor.

The Motor and Application Control Block is based on microprocessor software. The

microprocessor controls the motor basing on the information it receives through measurements,

parameter settings, control I/O and control keypad. The motor and application control block

controls the motor control ASIC which, in turn, calculates the IGBT positions. Gate drivers amplify

these signals for driving the IGBT inverter bridge.

Power

module

Brake resistor*

Mains

L1

L2

L3

1)

Integrated input module

Rectifier

3~

=

Charg.res.

Brake

Chopper*

2)

3)

IGBT

Inverter Current

Sensors

=

3~

Motor

U Output

V EMCfilter

W

Fan

Power

Supply

Measurements

Gate

Drivers

Voltage

Sensors

NXP

Control

Keypad

Control

module

Motor and

Application

Control

Motor

Control

ASIC

Control

I/O

Control

I/O

Control

I/O

Control

I/O

Control

I/O

*The brake resistor can be installed internally in classes FR4 to FR6 (NX_2 and NX_5). In all other

frames of voltage classes NX_2 and NX_5, as well as in all frames of all other voltage classes, the

brake resistor is available as option and installed externally.

Brake chopper belongs to the standard equipment in classes FR4 to FR6, while in greater classes

(FR7 to FR9) it is optional.

Figure 4-1. NX block diagram

Automation and Control Solutions

Honeywell

Honeywell Limited-Honeywell Limitée

1985 Douglas Drive North 35 Dynamic Drive

Golden Valley, MIN 55422 Scarborough, Ontario 63-2600-1

MIV 4Z9

www.honeywell.com

4

16(110) Technical data

The control keypad provides a link between the user and the frequency drive. The control keypad

is used for parameter setting, reading status data and giving control commands. It is detachable

and can be operated externally and connected via a cable to the frequency drive. Also a PC can

be used instead of the control keypad, to control the frequency drive, if connected through a

similar cable.

Control I/O boards which are either isolated (OPT-A8) or not isolated (OPT-A1) from the ground

are available.

The default application (Basic Application) is preferred when speed control will be dictated by a

separate automation system. If a more versatile interface or parameters are required, a more

suitable application can be chosen from the Application Package. See the Application Manual for

more information on the different applications.

A brake resistor is available as internal option for frames FR4 to FR6 of voltage classes NX_2 and

NX_5. In all other frames of voltage classes NX_2 and NX_5, as well as in all frames of all other

voltage classes, the brake resistor is available as option and installed externally.

Optional I/O expander boards that increase the number of inputs and outputs to be used are also

available. For details please contact your nearest Honeywell office or your local distributor (see

back cover).

The input and output EMC filters have no influence on the basic functions of the frequency drives

and significantly enhance the protection of the drive from external interference as well as

protecting other sensitive equipment from harmonics generated by the frequency drive. They are

also necessary for the fulfillment of the EMC directives.

4

Automation and Control Solutions

Honeywell

Honeywell Limited-Honeywell Limitée

1985 Douglas Drive North 35 Dynamic Drive

Golden Valley, MIN 55422 Scarborough, Ontario 63-2600-1

MIV 4Z9

www.honeywell.com

Technical data 17(110)

4.2 Power ratings

4.2.1 NX_5 – Mains voltage 380—500 V

Low overload = 150% starting torque, 2 sec/20 sec, 110% overloadability, 1 min/10 min

Following continuous operation at rated output current, 110% rated output current (IL)

for 1 min, followed by a period of load current less than rated current, and of such

duration that the r.m.s output current, over the duty cycle, does not exceed rated output

current (IL)

High overload = 200% starting torque, 2 sec/20 sec, 150% overloadability, 1 min/10 min

Following continuous operation at rated output current, 150 % rated output current (IH)

for 1 min, followed by a period of load current less than rated current, and of such

duration that the r.m.s output current, over the duty cycle, does not exceed rated output

current (IH)

All sizes up to and including FR9 are wall mounted available with NEMA1 enclosure and

NEMA12 as option. All sizes above and including FR10 are standalone NEMA 1 NXP units.

For single phase input connections, ratings and wiring instructions can be found in 6.2.1

Mains voltage 380-500 V, NEMA 1/12, EMC-level H

Frequency Motor shaft power (500V) and current

drive type Low overload High overload

P [Hp]

(500V)

I(L)

P [Hp]

(500V)

I(H)

I(max)

Size / prot. FR/IP

Dimensions

WxHxD

(in)

Weight

(lb)

NX_ 0015 A 1.5 3.3 1 2.2 4.4 FR4/NEMA 1/12 5.0x11.5x7.5 11.02

NX_ 0020 A 2 4.3 1.5 3.3 6.2 FR4/NEMA 1/12 5.0x11.5x7.5 11.02

NX_ 0030 A 3 5.6 2 4.3 8.6 FR4/NEMA 1/12 5.0x11.5x7.5 11.02

NX_ 0040 A 4 7.6 3 5.6 10.8 FR4/NEMA 1/12 5.0x11.5x7.5 11.02

NX_ 0050 A 5 9 4 7.6 14 FR4/NEMA 1/12 5.0x11.5x7.5 11.02

NX_ 0075 A 7.5 12 5 9 18 FR4/NEMA 1/12 5.0x11.5x7.5 11.02

NX_ 0100 A 10 16 7.5 12 24 FR5/NEMA 1/12 5.7x15.4x8.4 17.86

NX_ 0150 A 15 23 10 16 32 FR5/NEMA 1/12 5.7x15.4x8.4 17.86

NX_ 0200 A 20 31 15 23 46 FR5/NEMA 1/12 5.7x15.4x8.4 17.86

NX_ 0250 A 25 38 20 31 62 FR6/NEMA 1/12 7.7x20.4x9.3 40.8

NX_ 0300 A 30 46 25 38 76 FR6/NEMA 1/12 7.7x20.4x9.3 40.8

NX_ 0400 A 40 61 30 46 92 FR6/NEMA 1/12 7.7x20.4x9.3 40.8

NX_ 0500 A 50 72 40 61 122 FR7/NEMA 1/12 9.3x23.3x10.1 77.2

NX_ 0600 A 60 87 50 72 144 FR7/NEMA 1/12 9.3x23.3x10.1 77.2

NX_ 0750 A 75 105 60 87 174 FR7/NEMA 1/12 9.3x23.3x10.1 77.2

NX_ 1000 A 100 140 75 105 210 FR8/NEMA 1/12 11.2x28.4x11.3 127.9

NX_ 1250 A 125 170 100 140 280 FR8/NEMA 1/12 11.2x28.4x11.3 127.9

NX_ 1500 A 150 205 125 170 336 FR8/NEMA 1/12 11.2x28.4x11.3 127.9

NX_ 2000 A 200 261 150 205 349 FR9/NEMA 1/12 18.9x45.3x14.3 321.9

NX_ 2500 A 250 300 200 245 444 FR9/NEMA 1/12 18.9x45.3x14.3 321.9

NXP 3000 A 300 385 250 300 540 FR10/NEMA1 23.6x89.6x23.6 661.1

NXP 3500 A 350 460 300 385 693 FR10/NEMA1 23.6x89.6x23.6 661.1

NXP 4500 A 450 520 350 460 828 FR10/NEMA1 23.6x89.6x23.6 661.1

NXP 5000 A 500 590 450 520 936 FR11/NEMA1 31.6x79.4x23.6 815.7

NXP 5500 A 550 650 500 590 1062 FR11/NEMA1 31.6x79.4x23.6 815.7

NXP 6000 A 600 730 550 650 1170 FR11/NEMA1 31.6x79.4x23.6 815.7

NXP 6500 A 650 820 600 730 1314 FR12/NEMA1 47.6x 79.4x 23.6 1322.8

NXP 7000 A 700 920 650 820 1476 FR12/NEMA1 47.6x 79.4x 23.6 1322.8

NXP 8000 A 800 1030 700 920 1654 FR12/NEMA1 47.6x 79.4x 23.6 1322.8

Table 4-1. Power ratings and dimensions of the NX, supply voltage 380—500V.

Note: The rated currents in given ambient temperatures are achieved only when the switching frequency is

equal to or less than the factory default.

Note: The rated currents for FR10 to FR12 are all valid at an ambient temperature of 104 °F.

Automation and Control Solutions

Honeywell

Honeywell Limited-Honeywell Limitée

1985 Douglas Drive North 35 Dynamic Drive

Golden Valley, MIN 55422 Scarborough, Ontario 63-2600-1

MIV 4Z9

www.honeywell.com

4

18(110) Technical data

4.2.2 NX_6 – Mains voltage 525—690 V

High overload = Max current IS, 2 sec/20 sec, 150% overloadability, 1 min/10 min

Following continuous operation at rated output current, 150 % rated output current (IH)

for 1 min, followed by a period of load current less than rated current, and of such

duration that the r.m.s output current, over the duty cycle, does not exceed rated output

current (IH)

Low overload = Max current IS, 2 sec/20 sec, 110% overloadability, 1 min/10 min

Following continuous operation at rated output current, 110% rated output current (IL)

for 1 min, followed by a period of load current less than rated current, and of such

duration that the r.m.s output current, over the duty cycle, does not exceed rated output

ORIGINALRESEARCH

ImpactofpretreatmentPET on disease control

and treatment decisions in locoregionally

advanced esophageal cancer patients treated

with chemoradiotherapy

John M. Watkins et al p. 8

Variation by age in neutropenic

complications among patients with

cancer receiving chemotherapy

Henry J. Henk et al p. 16

COMMENTARY

Regorafenib monotherapy for previously

treated metastatic colorectal cancer

Stuart M. Lichtman, MD p. 3

COMMUNITY TRANSLATIONS

Regorafenib in previously treated

metastatic colorectal cancer

Edited by Jame Abraham, MD p. 5

FEATURES

Technology: LinkedIn Facebook

HIPPA friendly and secure Doximity

Neil Osterweil p. 33

Volume 10 ● Number 1 ● January 2013

There is an association between

pretreatmentPET and disease

control endpoints, including

locoregional control in esophageal

tumors treated with

chemoradiotherapy.

John M. Watkins p. 8

Oncologists should evaluate patient

comorbidities and chemotherapy

characteristics as well as age when

assessing the risks for neutropeniarelated

hospitalization.

Henry J. Henk p. 16

One of the caveats for regorafenib for

previously treated metastatic

colorectal is that none of the patients

in the trial were in their 70s, which

is the age range of most patients

with this disease.

Stuart M. Lichtman p. 3

Complete table of contents, page A7

COMMUNITY ONCOLOGY January 2013

Volume 10, Number 1 (pp 1–34)

For chronic lymphocytic leukemia (CLL)

refractory to fludarabine and alemtuzumab

EXPAND YOUR OPTIONS

A study population in need of additional treatment options 1,2

5 median

prior therapies

59%

93%

100%

The following serious adverse events (AEs) are discussed in greater detail below:

Infusion reactions, cytopenias, progressive multifocal leukoencephalopathy, hepatitis B

infection and reactivation, and intestinal obstruction.

To learn more, please visit www.ARZERRA.com.

Indication

ARZERRA (ofatumumab) is indicated for the treatment

of patients with chronic lymphocytic leukemia (CLL)

refractory to fludarabine and alemtuzumab.

The effectiveness of ARZERRA is based on the

demonstration of durable objective responses. No

data demonstrate an improvement in disease-related

symptoms or increased survival with ARZERRA.

Important Safety Information

Infusion Reactions

ARZERRA can cause serious infusion reactions manifesting

as bronchospasm, dyspnea, laryngeal edema, pulmonary

edema, flushing, hypertension, hypotension, syncope,

cardiac ischemia/infarction, back pain, abdominal pain,

pyrexia, rash, urticaria, and angioedema. Infusion reactions

occur more frequently with the first 2 infusions. Premedicate

with acetaminophen, an antihistamine, and a corticosteroid.

Interrupt infusion for infusion reactions of any severity.

Institute medical management for severe infusion reactions

including angina, or other signs and symptoms of myocardial

ischemia. In a study of patients with moderate to severe

chronic obstructive pulmonary disease, an indication for

which ARZERRA is not approved, 2 of 5 patients developed

Grade 3 bronchospasm during infusion. Infusion reactions

occurred in 44% of patients on the day of the first infusion

(300 mg), 29% on the day of the second infusion (2,000 mg),

and less frequently during subsequent infusions.

of patients received prior rituximab

of patients received prior alkylating agents

of patients received prior fludarabine and alemtuzumab

Cytopenias

Prolonged (≥1 week) severe neutropenia and

thrombocytopenia can occur with ARZERRA. Monitor

complete blood counts (CBC) and platelet counts at regular

intervals during therapy, and increase the frequency of

monitoring in patients who develop Grade 3 or 4 cytopenias.

Of 108 patients with normal neutrophil counts at baseline,

45 (42%) developed ≥Grade 3 neutropenia. Nineteen (18%)

developed Grade 4 neutropenia. Some patients experienced

new onset Grade 4 neutropenia >2 weeks in duration.

Progressive Multifocal Leukoencephalopathy

Progressive multifocal leukoencephalopathy (PML),

including fatal PML, can occur with ARZERRA. Consider

PML in any patient with new onset of or changes in

pre-existing neurological signs or symptoms. Discontinue

ARZERRA if PML is suspected and initiate evaluation for

PML including consultation with a neurologist, brain MRI,

and lumbar puncture.

Hepatitis B Infection and Reactivation

Fulminant and fatal hepatitis B virus (HBV) infection and

reactivation can occur in patients following treatment with

ARZERRA. Screen patients at high risk of HBV infection

before initiation of ARZERRA. Closely monitor carriers of

hepatitis B for clinical and laboratory signs of active HBV

infection during treatment with ARZERRA and for 6 to 12

months following the last infusion of ARZERRA. Discontinue

ARZERRA in patients who develop viral hepatitis or

When treated with ARZERRA monotherapy, 42% of patients with

CLL refractory to fludarabine and alemtuzumab achieved a partial response 1

Overall response rate with ARZERRA

60

50

40

30

20

10

42%

FLUDARABINE AND

ALEMTUZUMAB REFRACTORY

(n=59)

reactivation of viral hepatitis, and institute appropriate

treatment. Insuffi cient data exist regarding the safety of

administration of ARZERRA in patients with active hepatitis.

Intestinal Obstruction

Obstruction of the small intestine can occur in patients

receiving ARZERRA. Perform a diagnostic evaluation if

obstruction is suspected.

Immunizations

The safety of immunization with live viral vaccines during or

following administration of ARZERRA has not been studied.

Do not administer live viral vaccines to patients who have

recently received ARZERRA. The ability to generate an

immune response to any vaccine following administration

of ARZERRA has not been studied.

Most Common Adverse Reactions

In the pivotal study (total population, n=154) the most

common adverse reactions (≥10%, all grades) were

neutropenia, followed by pneumonia (23%), pyrexia (20%),

cough (19%), diarrhea (18%), anemia (16%), fatigue (15%),

dyspnea (14%), rash (14%), nausea (11%), bronchitis (11%),

and upper respiratory tract infections (11%).

Most Common Serious Adverse Reactions

In the pivotal study (total population, n=154), where

ARZERRA was administered at 2,000 mg beginning with the

second dose for 11 doses, the most common serious adverse

Patients had received a median of 5 prior therapies

The investigator-determined overall response rate

in patients with CLL refractory to fl udarabine and

alemtuzumab was 42% (99% CI: 26, 60)

There were no complete responses

The eff ectiveness of ARZERRA is based on the

demonstration of durable objective responses

No data demonstrate an improvement in disease-related

symptoms or increased survival with ARZERRA

6.5 months—median duration of response

(95% CI: 5.8, 8.3)

reactions were infections (including pneumonia and sepsis),

neutropenia, and pyrexia.

A total of 108 patients (70%) experienced bacterial, viral, or

fungal infections. A total of 45 patients (29%) experienced

≥Grade 3 infections, of which 19 (12%) were fatal. The

proportion of fatal infections in the fludarabine- and

alemtuzumab-refractory group was 17%.

Please see Brief Summary of Prescribing Information on

adjacent pages.

How Supplied: Available as 2 diff erent single-use glass vials

for dilution and intravenous administration. Each vial contains

either 100 mg ofatumumab in 5 mL of solution or 1,000 mg

ofatumumab in 50 mL of solution.

References: 1. ARZERRA (ofatumumab) [package insert]. Research Triangle Park,

NC: GlaxoSmithKline; 2011. 2. Tam CS, O’Brien S, Lerner S, et al. Leuk Lymph.

2007;48(10):1931-1939.

BRIEF SUMMARY

ARZERRA ® (ofatumumab) Injection, for intravenous infusion

The following is a brief summary only; see full prescribing information for

complete product information.

1 INDICATIONS AND USAGE

ARZERRA ® (ofatumumab) is indicated for the treatment of patients

with chronic lymphocytic leukemia (CLL) refractory to fludarabine and

alemtuzumab. The effectiveness of ARZERRA is based on the demonstration

of durable objective responses [see Clinical Studies (14) of full prescribing

information]. No data demonstrate an improvement in disease-related

symptoms or increased survival with ARZERRA.

4 CONTRAINDICATIONS

None.

5 WARNINGS AND PRECAUTIONS

5.1 Infusion Reactions ARZERRA can cause serious infusion reactions

manifesting as bronchospasm, dyspnea, laryngeal edema, pulmonary edema,

flushing, hypertension, hypotension, syncope, cardiac ischemia/infarction,

back pain, abdominal pain, pyrexia, rash, urticaria, and angioedema. Infusion

reactions occur more frequently with the first 2 infusions [see Adverse

Reactions (6.1)]. Premedicate with acetaminophen, an antihistamine, and a

corticosteroid [see Dosage and Administration (2.1, 2.4) of full prescribing

information]. Interrupt infusion for infusion reactions of any severity. Institute

medical management for severe infusion reactions including angina or other

signs and symptoms of myocardial ischemia [see Dosage and Administration

(2.3) of full prescribing information]. In a study of patients with moderate

to severe chronic obstructive pulmonary disease, an indication for which

ARZERRA is not approved, 2 of 5 patients developed Grade 3 bronchospasm

during infusion. 5.2 Cytopenias Prolonged (≥1 week) severe neutropenia and

thrombocytopenia can occur with ARZERRA. Monitor complete blood counts

(CBC) and platelet counts at regular intervals during therapy, and increase

the frequency of monitoring in patients who develop Grade 3 or 4 cytopenias.

5.3 Progressive Multifocal Leukoencephalopathy Progressive multifocal

leukoencephalopathy (PML), including fatal PML, can occur with ARZERRA.

Consider PML in any patient with new onset of or changes in pre-existing

neurological signs or symptoms. Discontinue ARZERRA if PML is suspected,

and initiate evaluation for PML including consultation with a neurologist,

brain MRI, and lumbar puncture. 5.4 Hepatitis B Infection and Reactivation

Fulminant and fatal hepatitis B virus (HBV) infection and reactivation can

occur in patients following treatment with ARZERRA. Screen patients at high

risk of HBV infection before initiation of ARZERRA. Closely monitor carriers

of hepatitis B for clinical and laboratory signs of active HBV infection during

treatment with ARZERRA and for 6 to 12 months following the last infusion

of ARZERRA. Discontinue ARZERRA in patients who develop viral hepatitis or

reactivation of viral hepatitis, and institute appropriate treatment. Insufficient

data exist regarding the safety of administration of ARZERRA in patients with

active hepatitis. 5.5 Intestinal Obstruction Obstruction of the small intestine

can occur in patients receiving ARZERRA. Perform a diagnostic evaluation

if obstruction is suspected. 5.6 Immunizations The safety of immunization

with live viral vaccines during or following administration of ARZERRA has

not been studied. Do not administer live viral vaccines to patients who have

recently received ARZERRA. The ability to generate an immune response to

any vaccine following administration of ARZERRA has not been studied.

6 ADVERSE REACTIONS

The following serious adverse reactions are discussed in greater detail in

other sections of the labeling:

• Infusion Reactions [see Warnings and Precautions (5.1)]

• Cytopenias [see Warnings and Precautions (5.2)]

• Progressive Multifocal Leukoencephalopathy [see Warnings and

Precautions (5.3)]

• Hepatitis B Reactivation [see Warnings and Precautions (5.4)]

• Intestinal Obstruction [see Warnings and Precautions (5.5)]

The most common adverse reactions (≥10%) in Study 1 were neutropenia,

pneumonia, pyrexia, cough, diarrhea, anemia, fatigue, dyspnea, rash,

nausea, bronchitis, and upper respiratory tract infections. The most common

serious adverse reactions in Study 1 were infections (including pneumonia

and sepsis), neutropenia, and pyrexia. Infections were the most common

adverse reactions leading to drug discontinuation in Study 1. 6.1 Clinical

Trials Experience Because clinical trials are conducted under widely varying

conditions, adverse reaction rates observed in the clinical trials of a drug

cannot be directly compared to rates in the clinical trials of another drug and

may not reflect the rates observed in practice. The safety of monotherapy

with ARZERRA was evaluated in 181 patients with relapsed or refractory

CLL in 2 open-label, non-randomized, single-arm studies. In these studies,

ARZERRA was administered at 2,000 mg beginning with the second dose

for 11 doses (Study 1 [n = 154]) or 3 doses (Study 2 [n = 27]). The data

described in Table 1 and other sections below are derived from 154 patients

in Study 1. All patients received 2,000 mg weekly from the second dose

onward. Ninety percent of patients received at least 8 infusions of ARZERRA

and 55% received all 12 infusions. The median age was 63 years (range: 41

to 86 years), 72% were male, and 97% were White.

Table 1. Incidence of All Adverse Reactions Occurring in ≥5% of Patients

in Study 1 and in the Fludarabine- and Alemtuzumab-Refractory Subset

of Study 1 (MedDRA 9.0)

Total Population

(n = 154)

All

Grades

%

Grade

≥3

%

Fludarabine- and

Alemtuzumab-

Refractory

(n = 59)

All

Grades

%

Grade

≥3

%

Body System/

Adverse Event

Infections and infestations

Pneumoniaa 23 14 25 15

Upper respiratory tract

infection

11 0 3 0

Bronchitis 11

7 DRUG INTERACTIONS

No formal drug-drug interaction studies have been conducted with ARZERRA.

8 USE IN SPECIFIC POPULATIONS

8.1 Pregnancy Pregnancy Category C: There are no adequate or well-controlled

studies ofofatumumab in pregnant women. A reproductive study in pregnant

cynomolgus monkeys that received ofatumumab at doses up to 3.5 times the

recommended human dose ofofatumumab did not demonstrate maternal

toxicity or teratogenicity. Ofatumumab crossed the placental barrier, and fetuses

exhibited depletion of peripheral B cells and decreased spleen and placental

weights. ARZERRA should be used during pregnancy only if the potential benefit

to the mother justifies the potential risk to the fetus. There are no human or

animal data on the potential short- and long-term effects of perinatal B-cell

depletion in offspring following in utero exposure to ofatumumab. Ofatumumab

does not bind normal human tissues other than B lymphocytes. It is not known

if binding occurs to unique embryonic or fetal tissue targets. In addition, the

kinetics of B-lymphocyte recovery are unknown in offspring with B-cell depletion

[see Nonclinical Toxicology (13.3)]. 8.3 Nursing Mothers It is not known whether

ofatumumab is secreted in human milk; however, human IgG is secreted in

human milk. Published data suggest that neonatal and infant consumption of

breast milk does not result in substantial absorption of these maternal antibodies

into circulation. Because the effects of local gastrointestinal and limited systemic

exposure to ofatumumab are unknown, caution should be exercised when

ARZERRA is administered to a nursing woman. 8.4 Pediatric Use Safety and

effectiveness of ARZERRA have not been established in children. 8.5 Geriatric

Use Clinical studies of ARZERRA did not include sufficient numbers of subjects

aged 65 and over to determine whether they respond differently from younger

subjects [see Clinical Pharmacology (12.3) of full prescribing information].

8.6 Renal Impairment No formal studies of ARZERRA in patients with renal

impairment have been conducted [see Clinical Pharmacology (12.3) of full

prescribing information]. 8.7 Hepatic Impairment No formal studies of ARZERRA

in patients with hepatic impairment have been conducted.

10 OVERDOSAGE

No data are available regarding overdosage with ARZERRA.

13 NONCLINICAL TOXICOLOGY

13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility No carcinogenicity

or mutagenicity studies ofofatumumab have been conducted. In a repeat-dose

toxicity study, no tumorigenic or unexpected mitogenic responses were noted in

cynomolgus monkeys treated for 7 months with up to 3.5 times the human dose

ofofatumumab. Effects on male and female fertility have not been evaluated

in animal studies. 13.3 Reproductive and Developmental Toxicology

Pregnant cynomolgus monkeys dosed with 0.7 or 3.5 times the human dose

ofofatumumab weekly during the period of organogenesis (gestation days

20 to 50) had no maternal toxicity or teratogenicity. Both dose levels of

ofatumumab depleted circulating B cells in the dams, with signs of initial

B cell recovery 50 days after the final dose. Following Caesarean section

at gestational day 100, fetuses from ofatumumab-treated dams exhibited

decreases in mean peripheral B-cell counts (decreased to approximately

10% of control values), splenic B-cell counts (decreased to approximately

15 to 20% of control values), and spleen weights (decreased by 15% for the

low-dose and by 30% for the high-dose group, compared to control values).

Fetuses from treated dams exhibiting anti-ofatumumab antibody responses

had higher B cell counts and higher spleen weights compared to the fetuses

from other treated dams, indicating partial recovery in those animals

developing anti-ofatumumab antibodies. When compared to control animals,

fetuses from treated dams in both dose groups had a 10% decrease in mean

placental weights. A 15% decrease in mean thymus weight compared to

the controls was also observed in fetuses from dams treated with 3.5 times

the human dose ofofatumumab. The biological significance of decreased

placental and thymic weights is unknown. The kinetics of B-lymphocyte

recovery and the potential long-term effects of perinatal B-cell depletion in

offspring from ofatumumab-treated dams have not been studied in animals.

17 PATIENT COUNSELING INFORMATION

Advise patients to contact a healthcare professional for any of the following:

• Signs and symptoms of infusion reactions including fever, chills, rash,

or breathing problems within 24 hours of infusion [see Warnings and

Precautions (5.1) and Adverse Reactions (6.1)]

• Bleeding, easy bruising, petechiae, pallor, worsening weakness, or fatigue

[see Warnings and Precautions (5.2)]

• Signs of infections including fever and cough [see Warnings and

Precautions (5.2) and Adverse Reactions (6.1)]

• New neurological symptoms such as confusion, dizziness or loss of

balance, difficulty talking or walking, or vision problems [see Warnings and

Precautions (5.3)]

• Symptoms of hepatitis including worsening fatigue or yellow discoloration

of skin or eyes [see Warnings and Precautions (5.4)]

• New or worsening abdominal pain or nausea [see Warnings and

Precautions (5.5)]

• Pregnancy or nursing [see Use in Specific Populations (8.1, 8.3)]

Advise patients of the need for:

• Periodic monitoring for blood counts [see Warnings and Precautions (5.2)]

• Avoiding vaccination with live viral vaccines [see Warnings and

Precautions (5.6)]

Manufactured by:

GLAXO GROUP LIMITED

Greenford, Middlesex, UB6 0NN, United Kingdom

U.S. Lic. 1809

Distributed by:

GlaxoSmithKline

Research Triangle Park, NC 27709

©2011, GlaxoSmithKline. All rights reserved.

September 2011

ARZ:6BRS

©2011 The GlaxoSmithKline Group of Companies

All rights reserved. Printed in USA. AZA293R0 September 2011

The Journal of Clinical Issues in Community Practice

Call for Papers

We are seeking papers in the following categories:

• Original Research • Reviews

• Letters • Case Letters

• Research Letters • Commentaries

To submit a paper, go to http://editorialmanager.com/co/

Editor-in-Chief

David H. Henry,

MD, FACP

Pennsylvania Hospital

Philadelphia

Editorial Board

Athanassios Argiris, MD

University of Texas Health Science Center, San Antonio

Ludovico Balducci, MD

Moffitt Cancer Center, Tampa, FL

Johanna Bendell, MD

Sarah Cannon Research Institute, Nashville, TN

Charles L. Bennett, MD, PhD, MPP

University of South Carolina, Columbia

Roy A. Beveridge, MD

US Oncology, Houston, TX

Ralph V. Boccia, MD

Georgetown University, Washington, DC

Matt Brow

US Oncology, Washington, DC

Leslie T. Busby, MD

Rocky Mountain Cancer Centers, Boulder, CO

Sant P. Chawla, MD, FRACP

Sarcoma Oncology Center Santa Monica, CA

Michael J. Fisch, MD, MPH

The University of Texas

MD Anderson Cancer Center, Houston

John A. Fracchia, MD

Lenox Hill Hospital, New York

James N. George, MD

University of Oklahoma Health Sciences Center

Oklahoma City

James Gilmore, PharmD

Georgia Cancer Specialists, Atlanta

Axel Grothey, MD

Mayo Clinic, Rochester, MN

Daniel G. Haller, MD

Professor Emeritus, University of Pennsylvania, Bryn Mawr

David M.J. Hoffman, MD

Tower Hematology Oncology Medical Group

Beverly Hills, CA

Jimmie Holland, MD

Memorial Sloan-Kettering Cancer Center, New York

Thomas Julian, MD

Allegheny General Hospital, Pittsburgh, PA

Vivek Kavadi, MD

Texas Oncology Cancer Center, Austin

Shaji Kumar, MD

Mayo Clinic, Rochester, MN

Kartik Konduri

Texas Oncology Cancer Center, Austin

Corey J Langer, MD, FACP

University of Pennsylvania, Philadelphia

Editors

Jame Abraham, MD

West Virginia University

Morgantown, WV

Linda D. Bosserman,

MD, FACP

Wilshire Oncology

Medical Group

La Verne, CA

January 2013

VOLUME 10, NUMBER 1

Debra A. Patt,

MD, MPH

Texas Oncology Cancer

Center, Austin

Stuart M. Lichtman, MD

Memorial Sloan-Kettering Cancer Center, Commack, NY

John L. Marshall, MD

Lombardi Comprehensive Cancer Center, Washington, DC

Cathy Maxwell, RN, OCN, CCRC

Advanced Medical Specialties, LLC, Miami, FL

Bradley J. Monk, MD, FACOG

Creighton University School of Medicine at St. Joseph’s Hospital and

Medical Center, Phoenix, AZ

Anne Moore, MD

Weill Medical College of Cornell University, New York

Eric Nadler, MD

Texas Oncology Cancer Center, Austin

Deborah A. Nagle, MD

Beth Israel Deaconess Medical Center, Boston, MA

Marcus Neubauer, MD

University of Kansas Cancer Center, Overland Park

Geoffrey R. Norman, PhD

McMaster University, Hamilton, Ontario, Canada

Steven O’Day, MD

The Angeles Clinic & Research Institute, Los Angeles, CA

Theodore A. Okon, MBA

Supportive Oncology Services, Memphis, TN

Philip A. Philip, MD, PhD

Barbara Ann Karmanos Cancer Institute, Detroit, MI

Jondavid Pollock, MD, PhD

Schiffler Cancer Center, Wheeling, WV

Nicholas J. Robert, MD

US Oncology, Fairfax, VA

Peter J. Rosen, MD

Roy & Patricia Disney Family

Cancer Research Center, Burbank, CA

Myrna R. Rosenfeld, MD, PhD

University of Pennsylvania School of Medicine, Philadelphia

Lee S. Schwartzberg, MD, FACP

The West Clinic, Memphis, TN

Mark A. Sitarik, MD

Rocky Mountain Cancer Centers, Boulder, CO

David Streiner, PhD, CPsych

University of Toronto, Toronto, Ontario, Canada

Debu Tripathy, MD

University of Southern California/ Norris Comprehensive Cancer Center,

Los Angeles

Steven Tucker, MD

Tucker Medical, Singapore, Malaysia

Volume 10/Number 1 January 2013 COMMUNITY ONCOLOGY A5

Information for Authors and Advertisers

Aims and Scope

COMMUNITY ONCOLOGY is an independent journal that publishes peerreviewed

research, review articles and commentary on all aspects of

clinical oncology practice. Article types include original clinical studies in

practice-based settings, state-of-the-art review papers, peer viewpoints,

commentaries, and letters to the editor.

For a full and complete guide for authors, go to ees.elsevier.com/co/

For further information, contact the Managing Editor, Renée Matthews,

at 240-221-2461 or e-mail, renee.matthews@elsevier.com.

Correspondence

For general, noneditorial enquiries, write to COMMUNITY ONCOLOGY, 7

Century Drive, Suite 302, Parsippany, NJ 07054-4609.

Letters to the Editor should be addressed to the Editor-in-Chief, David

H. Henry, MD, FACP, e-mail: c.oncology@elsevier.com.

Advertising

For information regarding advertising rates, contact Peter Murphy

(tel: 201-529-4020; e-mail: pmurphy@braveheart-group.com) or Stuart

Williams (tel: 201-529-4004; e-mail: swilliams@braveheart-group.com);

for information regarding supplements and projects, contact Devin

Gregorie (tel: 516-381-8613; e-mail: d.gregorie@elsevier.com).

CME Supplements

For information on CME supplements to COMMUNITY ONCOLOGY,

contact Sylvia Reitman of Global Academy for Medical Education,

LLC, at e-mail: s.reitman@globalacademycme.com.

Annual Subscription Rates

For 12 issues (in US$): Individual $380, Canada $413, International

$413; Institutional $380, Canada $413, International, $413; Single

copy $45.

For further information regarding subscriptions, contact Subscription

Inquiry Line 1-800-480-4851.

COMMUNITY ONCOLOGY (ISSN 1548-5315) is published monthly

by Frontline Medical Communications Inc, 7 Century Drive, Suite 302,

Parsippany, NJ 07054-4609.

January 2013

VOLUME 10, NUMBER 1

Copyright

© Copyright 2013 by Frontline Medical Communications Inc. No part

of this publication may be reproduced or transmitted in any form or by

any means, electronic or mechanical, including photocopy, recording, or

any information storage and retrieval system, without written permission

from the Publisher.

Disclaimer

Discussions, views, opinions, and recommendations as to medical

procedures, products, choice of drugs, and drug dosages are the

responsibility of the authors or advertisers. No responsibility is assumed

by the Publisher, Editor, or Editorial Board for any injury and/or

damage to persons or property as a matter of product liability,

negligence, or otherwise or from any use or operation of any methods,

products, instructions, or ideas contained in the material herein. Because

of rapid advances in the medical sciences, independent verification of

diagnoses and drug dosages should be made. Advertiser and advertising

agency recognize, accept, and assume liability for all content (including

text, representations, illustrations, opinions, and facts) of advertisements

printed and also assume responsibility for any claims made against the

Publisher arising from or related to such advertisements.

In the event that legal action or a claim is made against the Publisher

arising from or related to such advertisements, advertiser and advertising

agency agree to fully defend, indemnify, and hold harmless the Publisher

and to pay any judgment, expenses, and legal fees incurred by the

Publisher as a result of said legal action or claim. The Publisher reserves

the right to reject any advertising that he feels is not in keeping with the

publication’s standards.

The Publisher is not liable for delays in delivery and/or nondelivery in

the event of Act of God, action by any government or quasigovernmental

entity, fire, flood, insurrection, riot, explosion, embargo,

strikes (whether legal or illegal), labor or material shortage, transportation

interruption of any kind, work slowdown, or any condition beyond the

control of the Publisher that affects production or delivery in any

manner.

This journal is printed on paper meeting the requirements of ANSI/

NISO Z39.48-1992 (Permanence of Paper) effective with Volume 1,

Issue 1, 2004.

A6 COMMUNITY ONCOLOGY January 2013 www.CommunityOncology.net

Alan Imhoff, President and Publisher

Mary Jo Dales, Editorial Director

Reneé Matthews, Managing Editor

Neil Osterweil, Contributing Writer

Rebecca Slebodnik, Production Specialist

Peter Murphy, Stuart Williams, National

Accounts Managers

Devin Gregorie, National Accounts

Manager—Oncology Projects

a publication by IMNG Medical

Media, a division of Frontline

Medical Communications Inc.

COMMUNITY ONCOLOGY (ISSN 1548-5315) is

published monthly by Frontline Medical Communications

Inc, 7 Century Drive, Suite 302, Parsippany,

NJ 07054-4609. Periodicals postage paid at Parsippany,

NJ, and additional mailing offices.

Change of Address

Postmaster: send changes of address to COMMUNITY

ONCOLOGY, Subscription Service, 151 Fairchild Ave.,

Suite 2, Plainview, NY 11803-1709.

Recipient: to change your address, contact

Subscription Services 1-800-480-4851.

FROM THE EDITOR

1 From ASH, studies that advance the treatment of

hematologic malignancies

David H. Henry, MD, FACP

COMMENTARY

3 Regorafenib monotherapy for previously treated metastatic

colorectal cancer

Stuart M. Lichtman, MD

COMMUNITY TRANSLATIONS

5 Regorafenib in previously treated metastatic colorectal

cancer

Edited by Jame Abraham, MD; report prepared by Matt Stenger, MS

ORIGINALRESEARCH

January 2013

VOLUME 10, NUMBER 1

contents

8 ImpactofpretreatmentPET on disease control and

treatment decisions in locoregionally advanced esophageal

cancer patients treated with chemoradiotherapy

Patricia L. Watkins, MS, John M. Watkins, MD, A. Jason Zauls, MD,

Daniel T. Lackland, DrPH, M. Boyd Gillespie, MD, Thomas C. Hulsey, ScD,

and Joseph M. Jenrette III, MD

16 Variation by age in neutropenic complications among

patients with cancer receiving chemotherapy

Henry J. Henk, PhD, James A. Kaye, MD, DrPH, Kenneth J. Rothman, DrPH,

Laura K. Becker, MS, Jason C. Legg, PhD, Xiaoyan Li, PhD, and

Robert Deeter, PharmD

LETTERS

Case Letter

27 Plasmablastic lymphoma presenting as proptosis and

impending visual loss

Mihaela Vatca, MD, Katherine Robbins, MD, David D. Grier, MD,

James O. Cappellari IV, MD, and Seema Naik, MD

FEATURES

Technology

33 LinkedIn Facebook HIPPA friendly and secure Doximity

Neil Osterweil

Volume 10/Number 1 January 2013 COMMUNITY ONCOLOGY A7

For News and Views that

matter to supportive care

in oncology

Follow us on Twitter

@JSupportOncol

www.supportiveoncology.net

Important Safety Information

Serious adverse reactions associated with SYNRIBO

are myelosuppression (including thrombocytopenia,

neutropenia, and anemia), bleeding, and

hyperglycemia. Some adverse reactions, such as

myelosuppression, gastrointestinal hemorrhages,

and cerebral hemorrhage, have been severe and/or

fatal. Patients with neutropenia are at an increased

risk of infection

Closely monitor patient complete blood counts,

symptoms of infection or fever. Monitor glucose levels,

especially in patients with diabetes or risk factors for

diabetes. Avoid SYNRIBO in patients with poorly

controlled diabetes mellitus until good glycemic

control has been established. Consider dose

modifications for toxicities

©2012 Cephalon, Inc., a wholly owned subsidiary of Teva Pharmaceutical Industries Ltd.

All rights reserved. OMA-0027 November 2012. Printed in USA.

NOW APPROVED

SYNRIBO.com

SYNRIBO (omacetaxine mepesuccinate) for

Injection, for subcutaneous use, is indicated for

the treatment of adult patients with chronic or

accelerated phase chronic myeloid leukemia

(CML) with resistance and/or intolerance to

two or more tyrosine kinase inhibitors (TKIs).

This indication is based upon response rate.

There are no trials verifying an improvement in

disease-related symptoms or increased survival

with SYNRIBO.

SYNRIBO can cause fetal harm when administered

to a pregnant woman. Women should be advised to

avoid becoming pregnant while using SYNRIBO

Most common adverse reactions (frequency ≥20%)

in chronic and accelerated phase patients:

thrombocytopenia, anemia, neutropenia, diarrhea,

nausea, fatigue, asthenia, injection site reaction,

pyrexia, infection, and lymphopenia

Please see the following brief summary

of Prescribing Information.

BRIEF SUMMARY OF PRESCRIBING INFORMATION

See package insert for full Prescribing Information.

SYNRIBO (omacetaxine mepesuccinate) for Injection, for subcutaneous use

1 INDICATIONS AND USAGE

SYNRIBO is indicated for the treatment of adult patients with chronic or accelerated phase chronic

myeloid leukemia (CML) with resistance and/or intolerance to two or more tyrosine kinase inhibitors (TKI).

This indication is based upon response rate. There are no trials verifying an improvement in disease-related

symptoms or increased survival with SYNRIBO.

2 DOSAGE AND ADMINISTRATION

2.1 Induction Schedule

The recommended starting schedule for induction is 1.25 mg/m2 administered subcutaneously twice daily

for 14 consecutive days every 28 days, over a 28-day cycle. Cycles should be repeated every 28 days until

patients achieve a hematologic response.

2.2 Maintenance Dosing